Aptose Biosciences (NASDAQ:APTO) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a report published on Wednesday. The brokerage issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright restated a “buy” rating and issued a $2.00 target price on shares of Aptose Biosciences in a report on Tuesday, December 10th.

Aptose Biosciences Stock Up 3.2 %

Shares of APTO opened at $0.22 on Wednesday. Aptose Biosciences has a twelve month low of $0.13 and a twelve month high of $2.48. The firm has a 50 day moving average of $0.25 and a 200 day moving average of $0.41. The company has a market capitalization of $13.24 million, a P/E ratio of -0.07 and a beta of 0.87.

Institutional Investors Weigh In On Aptose Biosciences

A hedge fund recently raised its stake in Aptose Biosciences stock. Sigma Planning Corp raised its holdings in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 401,750 shares of the biotechnology company’s stock after acquiring an additional 167,282 shares during the quarter. Sigma Planning Corp owned approximately 2.22% of Aptose Biosciences worth $165,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 26.62% of the company’s stock.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.